Theranostics
13.3
Impact Factor
Global reach, higher impact
Theranostics 2024; 14(10):4127-4146. doi:10.7150/thno.97768 This issue Cite
Review
Biomarker-driven molecular imaging probes in radiotherapy
1. Department of Radiology, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
2. Functional and Molecular Imaging Key Laboratory of Sichuan Province and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu 610041, China.
3. Department of Radiology, West China Xiamen Hospital of Sichuan University, 699 Jinyuan Xi Road, Jimei District, 361021 Xiamen, Fujian, China.
Citation:
Li H, Gong Q, Luo K. Biomarker-driven molecular imaging probes in radiotherapy. Theranostics 2024; 14(10):4127-4146. doi:10.7150/thno.97768. https://www.thno.org/v14p4127.htm
Other stylesAbstract
Background: Biomarker-driven molecular imaging has emerged as an integral part of cancer precision radiotherapy. The use of molecular imaging probes, including nanoprobes, have been explored in radiotherapy imaging to precisely and noninvasively monitor spatiotemporal distribution of biomarkers, potentially revealing tumor-killing mechanisms and therapy-induced adverse effects during radiation treatment.
Methods: We summarized literature reports from preclinical studies and clinical trials, which cover two main parts: 1) Clinically-investigated and emerging imaging biomarkers associated with radiotherapy, and 2) instrumental roles, functions, and activatable mechanisms of molecular imaging probes in the radiotherapy workflow. In addition, reflection and future perspectives are proposed.
Results: Numerous imaging biomarkers have been continuously explored in decades, while few of them have been successfully validated for their correlation with radiotherapeutic outcomes and/or radiation-induced toxicities. Meanwhile, activatable molecular imaging probes towards the emerging biomarkers have exhibited to be promising in animal or small-scale human studies for precision radiotherapy.
Conclusion: Biomarker-driven molecular imaging probes are essential for precision radiotherapy. Despite very inspiring preliminary results, validation of imaging biomarkers and rational design strategies of probes await robust and extensive investigations. Especially, the correlation between imaging biomarkers and radiotherapeutic outcomes/toxicities should be established through multi-center collaboration involving a large cohort of patients.
Keywords: biomarker, molecular imaging, radiotherapy, imaging probe, nanoparticle
Citation styles
APA
Li, H., Gong, Q., Luo, K. (2024). Biomarker-driven molecular imaging probes in radiotherapy. Theranostics, 14(10), 4127-4146. https://doi.org/10.7150/thno.97768.
ACS
Li, H.; Gong, Q.; Luo, K. Biomarker-driven molecular imaging probes in radiotherapy. Theranostics 2024, 14 (10), 4127-4146. DOI: 10.7150/thno.97768.
NLM
Li H, Gong Q, Luo K. Biomarker-driven molecular imaging probes in radiotherapy. Theranostics 2024; 14(10):4127-4146. doi:10.7150/thno.97768. https://www.thno.org/v14p4127.htm
CSE
Li H, Gong Q, Luo K. 2024. Biomarker-driven molecular imaging probes in radiotherapy. Theranostics. 14(10):4127-4146.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.